Journal of Ginseng Research

  • 제47권4호
  • /
  • Pages.506-514
  • /
  • 2023
  • /
  • 1226-8453(pISSN)
  • /
  • 2093-4947(eISSN)
고려인삼학회 (The Korean Society of Ginseng)
권호 표지
DOI QR코드

DOI QR Code

Panax Ginseng in the treatment of Alzheimer's disease and vascular dementia

  • Zhiyong Wang (Department of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences) ;
  • Zhen Zhang (Department of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences) ;
  • Jiangang Liu (Department of Cardiovascular, Xiyuan Hospital, China Academy of Chinese Medical Sciences) ;
  • Mingdong Guo (Department of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences) ;
  • Hao Li (Wang Jing Hospital of China Academy of Chinese Medical Sciences)
  • 투고 : 2022.06.28
  • 심사 : 2023.03.15
  • 발행 : 2023.07.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Dementia has become one of the most important diseases threatening human health. Alzheimer's disease (AD) and vascular dementia (VaD) have the highest incidence rates among the types of dementia, but until now, therapeutic methods have been limited. Panax ginseng has been used in China for thousands of years to treat dementia, and modern medical studies have found that it contains multiple active components, such as ginsenosides, polysaccharides, amino acids, volatile oils and polyacetylenes, many of which have therapeutic effects in treating AD and VaD. Studies have found that ginsenosides have multitarget therapeutic effects in treating dementia, such as regulation of synaptic plasticity and the cholinergic system, inhibition of Aβ aggravation and tau hyperphosphorylation, anti-neuroinflammation, anti-oxidation effects and anti-apoptosis effects. Other active components of Panax ginseng, such as gintonin, oligosaccharides, polysaccharides and ginseng proteins, also have therapeutic effects on AD and VaD. The effectiveness of ginseng-containing Chinese medicine compounds has also been confirmed by clinical and basic investigations in treating AD and VaD. In this review, we summarized the potential therapeutic effects and related mechanisms of Panax ginseng in treating AD and VaD to provide some examples for further studies.

키워드

과제정보

This research was supported by the National Natural Science Foundation of China (NO: 82004434), Special training program for outstanding young scientific and technological talents (innovation) of China Academy of Chinese Medical Sciences (NO: ZZ-14-YQ-001), "Miao Pu" Foundation Project of Xiyuan Hospital, China Academy of Chinese Medical Sciences (NO: 2019XYMP-40), and cultivation project of Xiyuan Hospital for the National Natural Science Foundation project (XY20-08).

참고문헌

  1. Livingston G, Sommerlad A, Orgeta V, Costafreda S, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet 2017;390(10113):2673-734. https://doi.org/10.1016/S0140-6736(17)31363-6
  2. Cao Q, Tan CC, Xu W, Hu H, Cao XP, Dong Q, et al. The prevalence of dementia: a systematic review and meta-analysis. Journal of Alzheimer's Disease 2020;73(3):1157-66. https://doi.org/10.3233/JAD-191092
  3. Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, Li Y, Li Y, Zhu M, Jiao H, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet Public Health 2020;5(12):e661-71. https://doi.org/10.1016/S2468-2667(20)30185-7
  4. Tisher A, Salardini A. A comprehensive update on treatment of dementia. Seminars in Neurology 2019;39(2):167-78. https://doi.org/10.1055/s-0039-1683408
  5. Xu W, Choi H, Huang L. State of Panax ginseng research: a global analysis. Molecules 2017;22(9):1518.
  6. Liu H, Lu X, Hu Y, Fan X. Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy. Pharmacological Research 2020;161:105263.
  7. Flagg A. Traditional and current use of ginseng. The Nursing Clinics of North America 2021;56(1):109-21. https://doi.org/10.1016/j.cnur.2020.10.011
  8. Luan X, Zhang LJ, Li XQ, Rahman K, Zhang H, Chen HZ, Zhang WD. Compound-based Chinese medicine formula: from discovery to compatibility mechanism. Journal of Ethnopharmacol 2020;254:112687.
  9. Huang P, He X, Xu M. Dengzhan shengmai capsule combined with donepezil hydrochloride in the treatment of Alzheimer's disease: preliminary findings, randomized and controlled clinical trial. Revista da Associacao Medica Brasileira 2021;67(2):190-4. https://doi.org/10.1590/1806-9282.67.02.20200378
  10. Yang Y, Liu J, Fang J, Wang H, Wei Y, Cao Y, Liu J, Liu L, Li H. Effect and safety of Huannao Yicong formula in patients with mild-to-moderate Alzheimer's disease: a randomized, double-blinded, donepezil-controlled trial. Chinese Journal of Integrative Medicine 2019;25(8):574-81. https://doi.org/10.1007/s11655-018-3054-7
  11. Zhang H, Cao Y, Pei H, Wang H, Ma L, Wang Z, et al. Shenmayizhi formula combined with Ginkgo extract tablets for the treatment of vascular dementia: a randomized, double-blind, controlled trial. Evidence-Based complementary and alternative medicine 2020;2020:8312347.
  12. Mancuso C, Santangelo R. Panax ginseng and Panax quinquefolius: from pharmacology to toxicology. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association 2017;107:362-72. https://doi.org/10.1016/j.fct.2017.07.019
  13. Kim KH, Lee D, Lee HL, Kim CE, Jung K, Kang KS. Beneficial effects of Panax ginseng for the treatment and prevention of neurodegenerative diseases: past findings and future directions. Journal of Ginseng Research 2018;42(3):239-47. https://doi.org/10.1016/j.jgr.2017.03.011
  14. Christensen L. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Advances in Food and Nutrition Research 2009;55:1-99.
  15. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain : A Journal of Neurology 2018;141(7):1917-33. https://doi.org/10.1093/brain/awy132
  16. Joe E, Ringman JM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ 2019;367:l6217.
  17. Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. The Cochrane Database of Systematic Reviews 2021;2(2):Cd013306.
  18. Roman G, Kalaria R. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006;27(12):1769-85. https://doi.org/10.1016/j.neurobiolaging.2005.10.004
  19. Chen C, Zhang H, Xu H, Zheng Y, Wu T, Lian Y. Ginsenoside Rb1 ameliorates cisplatin-induced learning and memory impairments. Journal of Ginseng Research 2019;43(4):499-507. https://doi.org/10.1016/j.jgr.2017.07.009
  20. Chu S, Gu J, Feng L, Liu J, Zhang M, Jia X, Liu M, Yao D. Ginsenoside Rg5 improves cognitive dysfunction and beta-amyloid deposition in STZ-induced memory impaired rats via attenuating neuroinflammatory responses. International Immunopharmacology 2014;19(2):317-26. https://doi.org/10.1016/j.intimp.2014.01.018
  21. Kim MS, Yu JM, Kim HJ, Kim HB, Kim ST, Jang SK, Choi YW, Lee DI, Joo SS. Ginsenoside Re and Rd enhance the expression of cholinergic markers and neuronal differentiation in Neuro-2a cells. Biological & Pharmaceutical Bulletin 2014;37(5):826-33. https://doi.org/10.1248/bpb.b14-00011
  22. Shi J, Xue W, Zhao WJ, Li KX. Pharmacokinetics and dopamine/acetylcholine releasing effects of ginsenoside Re in hippocampus and mPFC of freely moving rats. Acta Pharmacologica Sinica 2013;34(2):214-20. https://doi.org/10.1038/aps.2012.147
  23. Jeon SJ, Lee HJ, Lee HE, Park SJ, Gwon Y, Kim H, Zhang J, Shin CY, Kim DH, Ryu JH. Oleanolic acid ameliorates cognitive dysfunction caused by cholinergic blockade via TrkB-dependent BDNF signaling. Neuropharmacology 2017;113:100-9. https://doi.org/10.1016/j.neuropharm.2016.07.029
  24. Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology 2008;33(1):18-41. https://doi.org/10.1038/sj.npp.1301559
  25. Skaper SD, Facci L, Zusso M, Giusti P. Synaptic plasticity, dementia and alzheimer disease. CNS & Neurological Disorders Drug Targets 2017;16(3):220-33. https://doi.org/10.2174/1871527316666170113120853
  26. Kozubski W, Ong K, Waleszczyk W, Zabel M, Dorszewska J. Molecular factors mediating neural cell plasticity changes in dementia brain diseases. Neural Plasticity 2021;2021:8834645.
  27. Sun M-K. Potential therapeutics for vascular cognitive impairment and dementia. Current Neuropharmacology 2018;16(7):1036-44. https://doi.org/10.2174/1570159X15666171016164734
  28. Sweatt JD. Neural plasticity and behavior - sixty years of conceptual advances. Journal of Neurochemistry 2016;139(Suppl 2):179-99. https://doi.org/10.1111/jnc.13580
  29. Zhu G, Wang Y, Li J, Wang J. Chronic treatment with ginsenoside Rg1 promotes memory and hippocampal long-term potentiation in middle-aged mice. Neuroscience 2015;292:81-9. https://doi.org/10.1016/j.neuroscience.2015.02.031
  30. Mook-Jung I, Hong HS, Boo JH, Lee KH, Yun SH, Cheong MY, Joo I, Huh K, Jung MW. Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. Journal of Neuroscience Research 2001;63(6):509-15. https://doi.org/10.1002/jnr.1045
  31. Yang L, Zhang J, Zheng K, Shen H, Chen X. Long-term ginsenoside Rg1 supplementation improves age-related cognitive decline by promoting synaptic plasticity associated protein expression in C57BL/6J mice. The Journals of Gerontology Series A, Biological Sciences and Medical Sciences 2014;69(3):282-94. https://doi.org/10.1093/gerona/glt091
  32. Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer's disease. Neural Regen Res 2022;17(3):543-9. https://doi.org/10.4103/1673-5374.320970
  33. Yu TW, Lane HY, Lin CH. Novel therapeutic approaches for Alzheimer's disease: an updated review. International Journal of Molecular Sciences 2021;22(15).
  34. Khan A, Kalaria R, Corbett A, Ballard C. Update on vascular dementia. Journal of Geriatric Psychiatry and Neurology 2016;29(5):281-301. https://doi.org/10.1177/0891988716654987
  35. Zhang H, Su Y, Sun Z, Chen M, Han Y, Li Y, Dong X, Ding S, Fang Z, Li W, et al. Ginsenoside Rg1 alleviates Aβ deposition by inhibiting NADPH oxidase 2 activation in APP/PS1 mice. J Ginseng Res 2021;45(6):665-75. https://doi.org/10.1016/j.jgr.2021.03.003
  36. Yun Y-J, Park B-H, Hou J, Oh J-P, Han J-H, Kim S-C. Ginsenoside F1 protects the brain against amyloid beta-induced toxicity by regulating IDE and NEP. Life (Basel) 2022;12(1):58.
  37. Ahn JW, Jang SK, Jo BR, Kim HS, Park JY, Park HY, Yoo YM, Joo SS. A therapeutic intervention for Alzheimer's disease using ginsenoside Rg3: its role in M2 microglial activation and non-amyloidogenesis. Journal of Physiology and Pharmacology 2021;72(2).
  38. Jang SK, Yu JM, Kim ST, Kim GH, Park DW, Lee DI, Joo SS. An Aβ42 uptake and degradation via Rg3 requires an activation of caveolin, clathrin and Aβ-degrading enzymes in microglia. European Journal of Pharmacology 2015;758:1-10. https://doi.org/10.1016/j.ejphar.2015.03.071
  39. Zong W, Zeng X, Chen S, Chen L, Zhou L, Wang X, Gao Q, Zeng G, Hu K, Ouyang D. Ginsenoside compound K attenuates cognitive deficits in vascular dementia rats by reducing the Aβ deposition. Journal of Pharmacological Sciences 2019;139(3):223-30. https://doi.org/10.1016/j.jphs.2019.01.013
  40. Li L, Li T, Tian X, Zhao L. Ginsenoside Rd attenuates tau phosphorylation in olfactory bulb, spinal cord, and telencephalon by regulating glycogen synthase kinase 3β and cyclin-dependent kinase 5. Evid Based Complement Alternat Med 2021;2021:4485957.
  41. Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. Clinical Biochemistry 2019;72:87-9. https://doi.org/10.1016/j.clinbiochem.2019.04.001
  42. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Archives of Pharmacal Research 2010;33(10):1539-56. https://doi.org/10.1007/s12272-010-1006-7
  43. Wang XX, Zhang B, Xia R, Jia QY. Inflammation, apoptosis and autophagy as critical players in vascular dementia. European Review for Medical and Pharmacological Sciences 2020;24(18):9601-14.
  44. Bennett S, Grant MM, Aldred S. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. Journal of Alzheimer's Disease 2009;17:245-57. https://doi.org/10.3233/JAD-2009-1041
  45. Aliev G, Priyadarshini M, Reddy V, Grieg N, Kaminsky Y, Cacabelos R, Ashraf G, Jabir N, Kamal M, Nikolenko V, et al. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Current Medicinal Chemistry 2014;21(19):2208-17. https://doi.org/10.2174/0929867321666131227161303
  46. Zhang Y, Ding S, Chen Y, Sun Z, Zhang J, Han Y, Dong X, Fang Z, Li W. Ginsenoside Rg1 alleviates lipopolysaccharide-induced neuronal damage by inhibiting NLRP1 inflammasomes in HT22 cells. Exp Ther Med 2021;22(1):782.
  47. Yang Y, Li S, Huang H, Lv J, Chen S, Pires Dias AC, Li Y, Liu X, Wang Q. Comparison of the protective effects of ginsenosides Rb1 and Rg1 on improving cognitive deficits in SAMP8 mice based on anti-neuroinflammation mechanism. Frontiers in Pharmacology 2020;11:834.
  48. Li C, Deng M, Gao Z, Dang Y, Zheng G, Yang X, Chao Y, Cai Y, Wu X. Effects of compound K, a metabolite of ginsenosides, on memory and cognitive dysfunction in db/db mice involve the inhibition of ER stress and the NLRP3 inflammasome pathway. Food & Function 2020;11(5):4416-27. https://doi.org/10.1039/C9FO02602A
  49. Jiao H, Jia J. Ginsenoside compound K acts via LRP1 to alleviate Amyloid β(42)-induced neuroinflammation in microglia by suppressing NF-κB. Biochemical and Biophysical Research Communications 2022;590:14-9. https://doi.org/10.1016/j.bbrc.2021.12.071
  50. Guo Q, He J, Zhang H, Yao L, Li H. Oleanolic acid alleviates oxidative stress in Alzheimer's disease by regulating stanniocalcin-1 and uncoupling protein-2 signalling. Clinical and Experimental Pharmacology & Physiology 2020;47(7):1263-71. https://doi.org/10.1111/1440-1681.13292
  51. Zhang L, Xia R, Jia J, Wang L, Li K, Li Y, Zhang J. Oleanolic acid protects against cognitive decline and neuroinflammation-mediated neurotoxicity by blocking secretory phospholipase A2 IIA-activated calcium signals. Molecular Immunology 2018;99:95-103. https://doi.org/10.1016/j.molimm.2018.04.015
  52. Mattson MP. Apoptosis in neurodegenerative disorders. Nature Reviews Molecular Cell Biology 2000;1(2):120-9. https://doi.org/10.1038/35040009
  53. Wang Y, Li Y, Yang W, Gao S, Lin J, Wang T, Zhou K, Hu H. Ginsenoside Rb1 inhibit apoptosis in rat model of Alzheimer's disease induced by Aβ(1-40). American Journal of Translational Research 2018;10(3):796-805.
  54. Shen F, Wang J, Gao F, Wang J, Zhu G. Ginsenoside Rg1 prevents cognitive impairment and hippocampal neuronal apoptosis in experimental vascular dementia mice by promoting GPR30 expression. Neural Plasticity 2021;2021:2412220.
  55. Alirezaei M, Kemball CC, Whitton JL. Autophagy, inflammation and neurodegenerative disease. Eur J Neurosci 2011;33(2):197-204. https://doi.org/10.1111/j.1460-9568.2010.07500.x
  56. Guo J, Chang L, Zhang X, Pei S, Yu M, Gao J. Ginsenoside compound K promotes β-amyloid peptide clearance in primary astrocytes via autophagy enhancement. Exp Ther Med 2014;8(4):1271-4. https://doi.org/10.3892/etm.2014.1885
  57. Jiang Y, Xie X, Huang P, Li B, Li H, Xia X. Mechanism of ginsenoside Rb1 activating mitophagy in PC12 cells injured by Ab. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology 2021;23(7):2319-26.
  58. Alkasir R, Li J, Li X, Jin M, Zhu B. Human gut microbiota: the links with dementia development. Protein Cell 2017;8(2):90-102. https://doi.org/10.1007/s13238-016-0338-6
  59. Wang L, Lu J, Zeng Y, Guo Y, Wu C, Zhao H, Zheng H, Jiao J. Improving Alzheimer's disease by altering gut microbiota in tree shrews with ginsenoside Rg1. FEMS Microbiology Letters 2020;367(4).
  60. Guo Y, Wang L, Lu J, Jiao J, Yang Y, Zhao H, Liang Z, Zheng H. Ginsenoside Rg1 improves cognitive capability and affects the microbiota of large intestine of tree shrew model for Alzheimer's disease. Molecular Medicine Reports 2021;23(4).
  61. Yang R, Jiang X, He X, Liang D, Sun S, Zhou G. Ginsenoside Rb1 improves cognitive impairment induced by insulin resistance through cdk5/p35-NMDAR-IDE pathway. Biomed Res Int 2020;2020:3905719.
  62. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig 2013;4(6):640-50. https://doi.org/10.1111/jdi.12087
  63. Jakaria M, Azam S, Go EA, Uddin MS, Jo SH, Choi DK. Biological evidence of gintonin efficacy in memory disorders. Pharmacological Research 2021;163:105221.
  64. Ikram M, Jo MG, Park TJ, Kim MW, Khan I, Jo MH, Kim MO. Oral administration of gintonin protects the brains of mice against ab-induced alzheimer disease pathology: antioxidant and anti-inflammatory effects. Oxidative Medicine and Cellular Longevity 2021;2021:6635552.
  65. Jang M, Choi S-H, Choi JH, Oh J, Lee RM, Lee N-E, Cho Y-J, Rhim H, Kim H-C, Cho I-H, et al. Ginseng gintonin attenuates the disruptions of brain microvascular permeability and microvascular endothelium junctional proteins in an APPswe/PSEN-1 double-transgenic mouse model of Аlzheimer's disease. Exp Ther Med 2021;21(4):310.
  66. Kim HJ, Kim DJ, Shin EJ, Lee BH, Choi SH, Hwang SH, Rhim H, Cho IH, Kim HC, Nah SY. Effects of gintonin-enriched fraction on hippocampal cell proliferation in wild-type mice and an APPswe/PSEN-1 double Tg mouse model of Alzheimer's disease. Neurochemistry International 2016;101:56-65. https://doi.org/10.1016/j.neuint.2016.10.006
  67. Kim HJ, Shin EJ, Lee BH, Choi SH, Jung SW, Cho IH, Hwang SH, Kim JY, Han JS, Chung C, et al. Oral administration of gintonin attenuates cholinergic impairments by scopolamine, amyloid-β protein, and mouse model of Alzheimer's disease. Molecules and Cells 2015;38(9):796-805. https://doi.org/10.14348/MOLCELLS.2015.0116
  68. Xu T, Shen X, Yu H, Sun L, Lin W, Zhang C. Water-soluble ginseng oligosaccharides protect against scopolamine-induced cognitive impairment by functioning as an antineuroinflammatory agent. J Ginseng Res 2016;40(3):211-9. https://doi.org/10.1016/j.jgr.2015.07.007
  69. Shin SJ, Nam Y, Park YH, Kim MJ, Lee E, Jeon SG, Bae BS, Seo J, Shim SL, Kim JS, et al. Therapeutic effects of non-saponin fraction with rich polysaccharide from Korean red ginseng on aging and Alzheimer's disease. Free Radical Biology & Medicine 2021;164:233-48. https://doi.org/10.1016/j.freeradbiomed.2020.12.454
  70. Li H, Kang T, Qi B, Kong L, Jiao Y, Cao Y, Zhang J, Yang J. Neuroprotective effects of ginseng protein on PI3K/Akt signaling pathway in the hippocampus of D-galactose/AlCl3 inducing rats model of Alzheimer's disease. Journal of Ethnopharmacology 2016;179:162-9. https://doi.org/10.1016/j.jep.2015.12.020
  71. Li H, Song J, Zhang J, Wang T, Yan Y, Tao Z, Li S, Zhang H, Kang T, Yang J. Ginseng protein reverses amyloid beta peptide and H(2) O(2) cytotoxicity in neurons, and ameliorates cognitive impairment in AD rats induced by a combination of D-galactose and AlCl(3). Phytotherapy Research 2017;31(2):284-95. https://doi.org/10.1002/ptr.5747
  72. Murata K, Iida D, Ueno Y, Samukawa K, Ishizaka T, Kotake T, Matsuda H. Novel polyacetylene derivatives and their inhibitory activities on acetylcholinesterase obtained from Panax ginseng roots. Journal of Natural Medicines 2017;71(1):114-22. https://doi.org/10.1007/s11418-016-1036-7
  73. Dong J. The relationship between traditional Chinese medicine and modern medicine. Evid Based Complement Alternat Med 2013;2013:153148.
  74. Zhou Y, Li X, Li Z, Lu M. Analysis of the prescription law of Chinese patent medicine to treat dementia. Chinese Journal of Modern Applied Pharmacy 2020;37(23):2883-7.
  75. Shin SJ, Jeon SG, Kim J-I, Jeong Y-O, Kim S, Park YH, Lee S-K, Park HH, Hong SB, Oh S, et al. Red ginseng attenuates ab-induced mitochondrial dysfunction and aβ-mediated pathology in an animal model of Alzheimer's disease. International Journal of Molecular Sciences 2019;20(12):3030.
  76. Lee M, Lee S-H, Kim M-S, Ahn K-S, Kim M. Effect of Lactobacillus dominance modified by Korean Red Ginseng on the improvement of Alzheimer's disease in mice. J Ginseng Res 2022;46(3):464-72. https://doi.org/10.1016/j.jgr.2021.11.001
  77. Choi JG, Kim N, Huh E, Lee H, Oh MH, Park JD, Pyo MK, Oh MS. White ginseng protects mouse hippocampal cells against amyloid-beta oligomer toxicity. Phytotherapy Research 2017;31(3):497-506. https://doi.org/10.1002/ptr.5776
  78. Wang L, Qiao P, Yue L, Sun R. Is Qi Fu Yin effective in clinical treatment of dementia?: a meta-analysis of 697 patients. Medicine (Baltimore) 2021;100(5):e24526-.
  79. Ngo FY, Wang W, Chen Q, Zhao J, Chen H, Gao JM, Rong J. Network pharmacology analysis and molecular characterization of the herbal medicine formulation qi-fu-yin for the inhibition of the neuroinflammatory biomarker iNOS in microglial BV-2 cells: implication for the treatment of Alzheimer's disease. Oxidative Medicine and Cellular Longevity 2020;2020:5780703.
  80. Xiao QY, Ye TY, Wang XL, Han L, Wang TX, Qi DM, Cheng XR, Wang SQ. A network pharmacology-based study on key pharmacological pathways and targets of Qi Fu Yin acting on Alzheimer's disease. Experimental Gerontology 2021;149:111336.
  81. Ren J, Wei D, An H, Zhang J, Zhang Z. Shenqi Yizhi granules protect hippocampus of AD transgenic mice by modulating on multiple pathological processes. Journal of Ethnopharmacology 2020;263:112869.
  82. Yang Y, Liu JP, Fang JY, Wang HC, Wei Y, Cao Y, Liu JG, Liu LT, Li H. Effect and safety of Huannao Yicong formula ( ) in patients with mild-to-moderate Alzheimer's disease: a randomized, double-blinded, donepezil-controlled trial. Chinese Journal of Integrative Medicine 2019;25(8):574-81. https://doi.org/10.1007/s11655-018-3054-7
  83. Wang Q, Li H, Wang FX, Gao L, Qin JC, Liu JG, Wei Y, Liu MX. Huannao Yicong Decoction extract reduces inflammation and cell apoptosis in Aβ(1-42)-induced Alzheimer's disease model of rats. Chinese Journal of Integrative Medicine 2017;23(9):672-80. https://doi.org/10.1007/s11655-016-2255-1
  84. Wang ZY, Liu JG, Wei Y, Liu MX, Wang Q, Liang L, Yang HM, Li H. Huannao Yicong Formula ( ) regulates γ-secretase activity through APH-1 and PEN-2 gene ragulation pathways in hippocampus of APP/PS1 double transgenic mice. Chinese Journal of Integrative Medicine 2017;23(4):270-8. https://doi.org/10.1007/s11655-017-2402-3
  85. Cao Y, Jia X, Wei Y, Liu M, Liu J, Li H. Traditional Chinese medicine Huannao Yicong decoction extract decreases tau hyperphosphorylation in the brain of Alzheimer's disease model rats induced by aβ(1-42). Evid Based Complement Alternat Med 2016;2016:6840432.
  86. Li H, Liu MF, Liu JG, Liu LT, Guan J, Cai LL, Hu J, Wei Y. Effect of Huannao Yicong prescription [See Text] extract on β-amyloid precursor protein metabolic signal transduction-related protein in brain tissue of dementia model transgenic mouse. Chinese Journal of Integrative Medicine 2012;18(9):683-9. https://doi.org/10.1007/s11655-012-1204-x
  87. Tian D, Guo Y, Zhang D, Gao Q, Liu G, Lin J, Chang Z, Wang Y, Su R, Han Z. Shenzhi Jiannao formula ameliorates vascular dementia in vivo and in vitro by inhibition glutamate neurotoxicity via promoting clathrin-mediated endocytosis. Chin Med 2021;16(1):65.
  88. Tian D, Gao Q, Lin J, Chang Z, Wang Y, Shi Y, Su R, Han Z, Ma D. Uncovering the mechanism of the Shenzhi Jiannao formula against vascular dementia using a combined network pharmacology approach and molecular biology. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 2021;90:153637.
  89. Tian D, Gao Q, Chang Z, Lin J, Ma D, Han Z. Network pharmacology and in vitro studies reveal the pharmacological effects and molecular mechanisms of Shenzhi Jiannao prescription against vascular dementia. BMC Complementary Medicine and Therapies 2022;22(1):33.
  90. Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Shi L, Gong M, Xu H, Li F, et al. Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: a randomized clinical trial. Alzheimers Dement 2018;4:108-17. https://doi.org/10.1016/j.trci.2018.02.004
  91. Zhang Y, Liu J, Yao M, Song W, Zheng Y, Xu L, Sun M, Yang B, Bensoussan A, Chang D, et al. Sailuotong capsule prevents the cerebral ischaemia-induced neuroinflammation and impairment of recognition memory through inhibition of LCN2 expression. Oxid Med Cell Longev 2019;2019:8416105.
  92. Fan XD, Yao MJ, Yang B, Han X, Zhang YH, Wang GR, Li P, Xu L, Liu JX. Chinese herbal preparation SaiLuoTong alleviates brain ischemia via Nrf2 anti-oxidation pathway-dependent cerebral microvascular protection. Frontiers in Pharmacology 2021;12:748568.
  93. Seto S, Chang D, Ko W, Zhou X, Kiat H, Bensoussan A, Lee S, Hoi M, Steiner G, Liu J. Sailuotong prevents hydrogen peroxide (H2O2)-Induced injury in EA.hy926 cells. International Journal of Molecular Sciences 2017;18(1).
  94. Zhang H, Cao Y, Pei H, Wang H, Ma L, Wang Z, Diao X, Yang Y, Liu N, Wei Y, et al. Shenmayizhi formula combined with Ginkgo extract tablets for the treatment of vascular dementia: a randomized, double-blind, controlled trial. Evid Based Complement Alternat Med 2020;2020:8312347.
  95. Sun C, Liu M, Liu J, Zhang T, Zhang L, Li H, Luo Z. ShenmaYizhi decoction improves the mitochondrial structure in the brain and ameliorates cognitive impairment in VCI rats via the AMPK/UCP2 signaling pathway. Neuropsychiatric Disease and Treatment 2021;17:1937-51. https://doi.org/10.2147/NDT.S302355
  96. Wu Q, Cao Y, Liu M, Liu F, Brantner AH, Yang Y, Wei Y, Zhou Y, Wang Z, Ma L, et al. Traditional Chinese medicine shenmayizhi decoction ameliorates memory and cognitive impairment induced by scopolamine via preventing hippocampal cholinergic dysfunction in rats. Neuropsychiatric Disease and Treatment 2019;15:3167-76. https://doi.org/10.2147/NDT.S214976